Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07169851 | A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer | PHASE2 | RECRUITING | 204 | — | — | Nov 28, 2025 | Feb 1, 2027 | Jun 4, 2026 | 67 | United States, Australia +8 |
CR defined as no vomiting and no rescue medication
| Arm | Type | Description |
|---|---|---|
| LY3537021 + Antiemetic Therapies | EXPERIMENTAL | Prior to chemotherapy, participants receive LY3537021 administered subcutaneously (SC) with standard of care (SOC) antiemetic therapies orally, intravenously (IV), or transdermally, per local label |
| Placebo + Antiemetic Therapies | PLACEBO_COMPARATOR | Prior to chemotherapy, participants receive placebo administered SC with SOC antiemetic therapies orally, IV, or transdermally, per local label |
| Name | Type | Description |
|---|---|---|
| LY3537021 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
| Standard of Care Antiemetic Therapies | DRUG | 5-HT3 Receptor Antagonist, NK1 Receptor Antagonist, Dexamethasone administered orally, IV, or transdermally |
| Background Chemotherapy | DRUG | Cisplatin or anthraxyline and cyclophosphamide (AC) administered IV |
Inclusion Criteria: * Chemotherapy-naive participants, planned to receive AC or cisplatin-based chemotherapy greater than or equal to (≥)70 milligrams per square meter (mg/m²), on Day 1 of each cycle, with no multiple administrations during the CINV observation period, from Day 2 to Day 5 of each c...